Acquired haemophilia is a spontaneous development of inhibitors or antibodies to ones own FVIII. Acquired haemophilia occurs in about one person per 1.5 million and both females and males can be affected. The underlying cause of inhibitor development is usually unknown but certain conditions may act as “triggers”, e.g. pregnancy, autoimmune disease, cancer, or the use of certain medications. Patients with acquired haemophilia may present to the hospital because of a severe spontaneous bleeding episode. These bleeding episodes are very difficult to control, and can often not be treated with FVIII. Agents that bypass the coagulation process which is inhibited by the antibody can be used to treat patients with acquired haemophilia.
HQMMA/N7/0914/0067. November 2014.